Search This Blog

Thursday, June 7, 2018

Mesoblast started at buy by Wainwright


Mesoblast initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Jason Kolbert started Mesoblast with a Buy rating and $17 price target. The analyst sees Mesoblast as having the strongest pipeline in the regenerative medicine space.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)